As 2024 draws to a close, DDW’s Multimedia Editor and podcast host Megan Thomas rounds up all the free editorial episodes of the DDW podcast that were released.

You can find The Drug Discovery World Podcast on Spotify, Google Play and Apple Podcasts.

DDW Highlights

Innovative. Evolving. Developing. Busy. These are just some of the words that come to mind when talking about not just the drug discovery sector, but the lives of those working in and around it. You can tune in every week to DDW Highlights for a roundup of industry news and updates. Episodes are released weekly. Catch up on previous weeks here.

Moreover, it is now also available in a concise vodcast format.

In Conversation With

For the In Conversation With series, Thomas speaks with members of the drug discovery industry about their work and how it helps turn science into business.

The first episode of 2024 was Developing novel targeted radiopharmaceuticals for cancer treatment. In this episode, Thomas is in conversation with Manfred Ruediger, CEO of Ariceum Therapeutics discussing the future of the company and its therapeutic pipeline. Listen here.

Next came a topic which continues to generate discourse and debate in the industry, a conversation with Dr Lynn Kirkpatrick, CEO of Ensysce Biosciences, on finding a safer option to opioid pain killers. Dr Kirkpatrick talks about Ensysce’s alternative to opioids and how it prevents abuse and overdose. Listen here.

Quin Wills, Co-founder and CSO of Ochre Bio, spoke on the podcast about the potential of complex human liver data. Ochre’s lab in Oxford takes different types of human cells from donor livers, which they combine to build components of the liver from scratch. These ‘bottom up’ models allow them to flexibly study the metabolic, cell death, inflammation, fibrosis, and neoplastic processes that occur throughout the liver disease trajectory. Listen here.

Exploring the potential of a new class of drug candidates was an episode featuring Ahmed Mousa, CEO of Vicore Pharma, where he gave an overview of the company’s unique approach, its challenges, its opportunities, and its context in the scientific community for a new class of drug candidates, angiotensin II type 2 receptor agonists (ATRAGs). Listen here.

eFFECTOR is a company targeting three distinct targets central to the eIF4F translation initiation complex: MNK, eIF4A and eIF4E. Its CEO Steve Worland discussed how Selective Translation Regulator Inhibitors (STRIs) are unique to other cancer treatments, the future of the industry as well as the significance of pharma collaboration in the development process. Listen here.

GLP-1 drugs are an increasingly ‘hot’ topic in 2024 and in this episode Thomas was in conversation with Tien Lee, CEO of Aardvark Therapeutics, a biotech in Phase II studies of its drug, ARD-101, a type 2 bitter taste receptor (TAS2R) which is taken orally and remains in the human gut – unlike GLP-1. Listen here.

Dr Friso Postma, Vice President of AI Drug Discovery at BioXcel Therapeutics, asks: Are we close to an AI drug revolution? In this episode, Postma discusses how the company’s AI platform was able to repurpose previous drugs to obtain FDA approval for its acute treatment for agitation associated with schizophrenia and bipolar disorder, IGALMI, in April 2022, which was the first drug development success that involved the actual use of AI. Listen here.

The unmet critical need for concussion drug therapies is a conversation with CEO of Oxeia, Dr Michael  Wyand, where he talks about Oxeia’s work; the unmet critical need for concussion drug therapies; the challenges facing them, including in clinical trials and investment; the potential market for concussion drugs, and more. Listen here.

Owen Smith, Partner at 4BIO Capital, came on the DDW podcast to discuss investment trends for drug discovery and development. Listen here.

Narrated podcast

Every issue of DDW is narrated, with a range of episodes published in 2024, including:

  1. Revolutionary technology for drug discovery and development
  2. Why is Europe a drug discovery epicentre?
  3. What trends will speed up the journey from clinic to bedside?
  4. Flow cytometry for drug discovery research
  5. A look behind the scenes of the drug discovery industry
  6. The future climate and landscape for drug discovery
  7. Why drug repurposing is so significant for drug discovery
  8. How to utilise clinical trials in drug discovery
  9. Shining a spotlight on cancer research developments
  10. Where is the global innovation and the opportunity in CGTs?
  11. Innovation drivers and opportunities for drug discovery
  12. How technology is impacting drug discovery
  13. The consistency and value of immunotherapy
  14. How to streamline regulatory approval
  15. Exciting start-ups and developments in drug discovery
  16. The far-reaching impact of drug discovery technology
  17. New ways of looking at effective cancer treatment